A Phase 1 interventional study of Myoinositol and Metformin in Polycystic Ovarian Syndrome (PCOS), sponsored by Fatima Tariq. Not yet recruiting at 1 site in Pakistan. Open to female participants aged 16 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Fatima Tariq · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing inositol in Polycystic Ovary Syndrome — 5 open to participants now, 6 under way, 1 of them phase 3. Inositol · Polycystic Ovary Syndrome.
Among the 33 studies testing inositol in Polycystic Ovary Syndrome, this one is the 18th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1, and was the 28th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →5 of the 33 studies testing inositol in Polycystic Ovary Syndrome are open now, in 4 countries. Recruiting first, the newest first:
Istanbul Health and Technology University · Sites in Turkey
Ages 18–40 · Women only · Healthy volunteers
University Hospital, Lille · Sites in France
Ages 18–35 · Women only
American University of Beirut Medical Center · Sites in Lebanon
Ages 18–18 · Women only · Healthy volunteers
Università degli Studi dell'Insubria
Ages 18–40 · Women only · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 16 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 2011; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 73 across the 32 interventional studies. Of the 24 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 33 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Fatima Tariq as lead sponsor.
Fatima Tariq has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies testing inositol in Polycystic Ovary Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03059173Phase 3University Hospital, LilleInterest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome | 2027-09-12 |
| NCT07896642Istanbul Health and Technology UniversityBrown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography | 2026-12 |
| NCT07604779Beni-Suef UniversityEnhancing PCOS Management for Better Outcomes of Intracytoplasmic Sperm Injection | 2026-12-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies testing inositol in Polycystic Ovary Syndrome, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound.
The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Informed consent will be obtained from each female. Demographic data (name, age, height and weight for BMI, duration of symptoms (irregular cycles from how many months), marital status, parity, residence, socioeconomic status, diet pattern, family history of PCOS, and life style will be recorded. Females will be asked for their menstrual cycle duration and irregularity. Females will be prescribed oral myoinositol 1g twice daily for 3 months. All females will be followed-up in OPD for 3 months. After 3 months, females will be asked for their menstrual cycle duration and regularity. Reports will be assessed and levels will be recorded. If females will have regular cycles, then it will be noted. Females will be asked to give a blood sample on 3rd day of menstrual cycle and LH/FSH ratio will be noted. All this data will be recorded in a specially designed proforma
Drug: Myoinositol
Informed consent will be obtained from each female. Demographic data (name, age, height and weight for BMI, duration of symptoms (irregular cycles from how many months), marital status, parity, residence, socioeconomic status, diet pattern, family history of PCOS, and life style will be recorded. Females will be asked for their menstrual cycle duration and irregularity. Females will be prescribed oral sustained-release metformin 850 mg twice daily for 3 months. All females will be followed-up in OPD for 3 months. After 3 months, females will be asked for their menstrual cycle duration and regularity. Reports will be assessed and levels will be recorded. If females will have regular cycles, then it will be noted. Females will be asked to give a blood sample on 3rd day of menstrual cycle and LH/FSH ratio will be noted. All this data will be recorded in a specially designed proforma.
Drug: Metformin
In group A, females will be prescribed oral myoinositol 1g twice daily for 3 months.
In group B, females will be prescribed oral sustained-release metformin 850 mg twice daily for 3 months.
LH/FSH ratio
It will be assessed in terms of ratio between LH and FSH after 3 months of treatment.
Time frame: 3 Months
Regular cycles
It will be labeled if number of days from the start (day 1) of one period until the start (day 1) of the next period are almost equal for at least 3 months
Time frame: 3 Months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Jul 2026, 2 months later.
Of 27 phase 1 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 147. This study's planned 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inositol